Myxedema Coma Market size is poised to reach USD 5 Billion by the end of 2035, growing at a CAGR of 4% during the forecast period, i.e., 2023 – 2035. In the year 2022, the industry size of myxedema coma was USD 2 Billion. The reason behind the growth is impelled by a higher prevalence of diabetes 1. Type 1 diabetes could be linked to other diseases including Hashimoto’s thyroiditis, which is considered a major cause of hypothyroidism. Moreover, it causes damage to the thyroid gland and may reduce the level of thyroid hormones in the body. Globally, there were approximately 7 million people with type 1 diabetes in 2021.
The growing geriatric population is believed to fuel the myxedema coma market growth. The elderly population is more prone to thyroid dysfunction and other age-related diseases such as diabetes which may increase the risk of myxedema coma. Lately, over 8% of the world's population, is over the age of 65, and by 2050, this ratio is anticipated to rise to around 15%.
Base Year |
2022 |
Forecast Year |
2023-2035 |
CAGR |
~4% |
Base Year Market Size (2022) |
~ USD 2 Billion |
Forecast Year Market Size (2035) |
~ USD 5 Billion |
Regional Scope |
|
Growth Drivers
Challenges
Route of Administration (Oral, Injectable)
The oral segment in the myxedema coma market is estimated to gain a robust revenue share in the coming years owing to the growing preference of people for oral therapy. Compared to intravenous treatments, oral drugs carry a lesser risk of problems including infection or vein damage. A post-injection flare is thought to occur in about 2 in 50 persons a few hours after receiving an injection. The convenience of consuming oral drugs and the cost-effectiveness also propels the segment’s growth.
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies)
Myxedema coma market from the hospital pharmacies segment is set to garner a notable share shortly. Thyroid hormone replacement therapy, which is the drug used to treat myxedema coma, is commonly accessible in hospital pharmacies where patients receive for this potentially fatal illness. Moreover, levothyroxine (T4) and liothyronine (T3) hormones, along with other medications used to treat myxedema coma, are often taken with the assistance of a medical practitioner. The effectiveness of the patient’s treatment must be closely monitored, and the dosage of the medicine should be changed as necessary.
Our in-depth analysis of the global myxedema coma market includes the following segments:
Route of Administration |
|
Indication |
|
Distribution Channel |
|
Drug Class |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this Report
North American Market Forecast
Myxedema coma market in North America is predicted to account for the largest share of 38% by the end of 2035 impelled by the growing prevalence of obesity. In the USA, obesity is a significant public health issue, which affects over 30% of Americans. Moreover, patients with obesity have a higher chance of developing hypothyroidism which may lead to myxedema coma if left untreated. According to the estimates, during the COVID-19 pandemic, the obesity rate in the U.S. increased by over 2% in 2021.
APAC Market Statistics
The Asia Pacific myxedema coma market is estimated to be the second largest, during the forecast timeframe led by a higher prevalence of iodine deficiency. One of the most frequent causes of hypothyroidism in the globe is iodine deficiency, which is highly prevalent in several nations in the Asia Pacific region such as South and Southeast Asia. As a result, iodine supplementation and thyroid hormone replacement therapy are becoming popular in the region.
For instance, no state in India is immune to iodine deficiency, and more than 150 million people are in danger' of developing iodine deficiency.
Author Credits: Radhika Gupta, Shivam Bhutani
Ans: Higher prevalence of type 1 diabetes and the growing geriatric population are the major factors driving the growth of the market.
Ans: The market size of myxedema coma is anticipated to attain a CAGR of 4% over the forecast period, i.e., 2023 – 2035.
Ans: The major players in the market are Merck & Co., Inc., Pfizer Inc., GSK plc., Sanofi Global, Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG, Lannett Company, Inc., Zydus Lifesciences.
Ans: The oral segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Ans: : The major players in the market are AbbVie Inc., Merck & Co., Inc., Pfizer Inc., GSK plc., and more.
Ans: The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?